530207 BRAWN

Brawn Biotech Share Price

 

 

Start SIP in BRAWN

Start SIP

Performance

  • Low
  • ₹21
  • High
  • ₹23
  • 52 Week Low
  • ₹15
  • 52 Week High
  • ₹25
  • Open Price₹23
  • Previous Close₹22
  • Volume1,210

Investment Returns

  • Over 1 Month + 4.89%
  • Over 3 Month + 5.93%
  • Over 6 Month + 27.63%
  • Over 1 Year -5.18%

Smart Investing Starts Here Start SIP with Brawn Biotech for Steady Growth!

Invest Now

Brawn Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -10.3
  • PEG Ratio
  • -0.2
  • Market Cap Cr
  • 6
  • P/B Ratio
  • 1.7
  • Average True Range
  • 0.94
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.02
  • RSI
  • 54.99
  • MFI
  • 82.2

Brawn Biotech Financials

Brawn Biotech Technicals

EMA & SMA

Current Price
₹21.25
-0.74 (-3.37%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹21.04
  • 50 Day
  • ₹20.90
  • 100 Day
  • ₹20.47
  • 200 Day
  • ₹20.04

Resistance and Support

21.36 Pivot Speed
  • R3 24.51
  • R2 23.25
  • R1 22.62
  • S1 20.73
  • S2 19.47
  • S3 18.84

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Brawn Biotech has an operating revenue of Rs. 16.79 Cr. on a trailing 12-month basis. An annual revenue de-growth of -18% needs improvement, Pre-tax margin of -13% needs improvement, ROE of -51% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Brawn Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-13 Quarterly Results
2025-05-26 Audited Results
2025-02-12 Quarterly Results
2024-11-14 Quarterly Results

Brawn Biotech F&O

Brawn Biotech Shareholding Pattern

53.66%
0.35%
32.9%
13.09%

Brawn Biotech FAQs

Brawn Biotech share price is ₹21 As on 31 December, 2025 | 14:16

The Market Cap of Brawn Biotech is ₹6.4 Cr As on 31 December, 2025 | 14:16

The P/E ratio of Brawn Biotech is -10.3 As on 31 December, 2025 | 14:16

The PB ratio of Brawn Biotech is 1.7 As on 31 December, 2025 | 14:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23